Explore

Alzheimer's Disease Staging Revolutionized by Biomarker Integration, UCLA Expert Explains

Alzheimer's Disease Staging Revolutionized by Biomarker Integration, UCLA Expert Explains

David Reuben, MD, Archstone Professor of Geriatrics at the David Geffen School of Medicine at UCLA, highlights a revolutionary shift in Alzheimer's disease staging. Historically, Alzheimer's was diagnosed clinically when symptoms like memory loss and personality changes were evident and dementia was advanced. However, over the past two decades, research has increasingly focused on biological biomarkers that can detect changes in the brain up to 20 years before symptoms appear. Current classification now combines clinical and biological definitions, resulting in six distinct stages. The first two stages are cognitively unimpaired, with stage one showing biological markers without symptoms and stage two including very minor cognitive issues within the normal range. Stage three marks mild cognitive impairment, followed by three categories of dementia. Dr. Reuben emphasizes that functional impairment is the key differentiator between mild cognitive impairment and dementia, where deficits begin to interfere wit...

WashU Medicine Researchers Link Blood Protein to Chronic Traumatic Encephalopathy (CTE)

WashU Medicine Researchers Link Blood Protein to Chronic Traumatic Encephalopathy (CTE)

Researchers at Washington University School of Medicine in St. Louis have identified a protein fragment in the blood, eMTBR-tau243, that is elevated in individuals with advanced chronic traumatic encephalopathy (CTE). This discovery, published in JAMA, marks a significant step towards diagnosing CTE in living patients, a condition currently only confirmable post-mortem. The study, led by co-senior authors Kanta Horie, PhD, and Chihiro Sato, PhD, found that this biomarker, previously linked to Alzheimer's disease, also indicates the presence of CTE and some inherited forms of frontotemporal dementia. The research involved testing eMTBR-tau243 levels in samples from 229 participants, including those with confirmed brain diseases and healthy volunteers. While the test accurately distinguished advanced CTE from healthy individuals, it was less reliable in identifying early-stage CTE. The findings suggest that this biomarker could be crucial for monitoring at-risk individuals and facilitating drug trials for ta...

Liver-Derived Protein APOA1 Shows Promise in Protecting Brain Cells and Improving Memory in Alzheimer's Mice

Liver-Derived Protein APOA1 Shows Promise in Protecting Brain Cells and Improving Memory in Alzheimer's Mice

Researchers from Gladstone Institutes, the University of California, San Francisco, the Buck Institute for Research on Aging, and Emory University, in collaboration with institutions in China, have identified a liver-derived protein, apolipoprotein A1 (APOA1), that shows potential in protecting brain cells and improving memory in mouse models of Alzheimer's disease. The study, published in the journal Cell, characterized how proteins are transported across the blood-brain barrier (BBB) and how this process is altered in Alzheimer's. They found that increasing APOA1 production in the liver of 5xFAD mice, a model for Alzheimer's, led to increased APOA1 levels in the liver, blood, and brain. This intervention resulted in decreased astrocytic lipid accumulation, reduced glial fibrillary acidic protein (GFAP) levels, and lower brain interleukin-1 beta (IL-1β) concentrations. Furthermore, soluble vascular amyloid-beta 42 (Aβ42) levels and hippocampal dentate gyrus plaque burden decreased, and synaptic density in...

Kaiser Permanente Secures $55.8 Million Grant for Brain Aging Research to Combat Dementia

Kaiser Permanente Secures $55.8 Million Grant for Brain Aging Research to Combat Dementia

Kaiser Permanente has received a significant funding boost of $55.8 million from the National Institute on Aging to extend its landmark Adult Changes in Thought Study. This study, which has been ongoing for over 30 years, focuses on understanding and preventing dementia. More than 7,000 Kaiser Permanente members aged 65 and older in Washington state participate, undergoing biennial study visits. The research has already yielded crucial insights, such as the role of regular exercise in lowering dementia risk and the potential impact of high blood sugar levels, hearing and vision loss, air pollution, and certain medications in increasing it. Over 1,000 participants have also donated their brains to the study, providing invaluable data for scientists to examine age-related brain changes and dementia progression. The new funding will support the study through June 2031, allowing researchers to delve deeper into the interplay between heart and blood vessel conditions (like high blood pressure and diabetes) and ...

University of Missouri Scientists Discover Transplant Drug Improves Brain Blood Flow in Alzheimer's Risk Group

University of Missouri Scientists Discover Transplant Drug Improves Brain Blood Flow in Alzheimer's Risk Group

Scientists at the University of Missouri have found that rapamycin, a drug typically used to prevent organ transplant rejection, improved brain blood flow in middle-aged adults carrying a genetic risk factor for Alzheimer's disease. The study, published in the Journal of Cerebral Blood Flow & Metabolism, involved adults aged 45 to 65 who received low daily doses of rapamycin for four weeks. The most notable improvements were observed in individuals with the APOE4 variant, particularly women, who are disproportionately affected by Alzheimer's. According to Ai-Ling Lin, PhD, a professor at the University of Missouri School of Medicine, this finding suggests a potential strategy to target brain changes years before the onset of memory problems, especially in those most at risk due to genetic predispositions. The research highlights a precision medicine approach, aiming to identify individuals who could benefit most from such interventions.

Digital Memory Tests Show Promise in Detecting Early Cognitive Changes in Preclinical Alzheimer's Disease Trials

Digital Memory Tests Show Promise in Detecting Early Cognitive Changes in Preclinical Alzheimer's Disease Trials

New research suggests that digital cognitive assessments could be valuable tools for identifying individuals likely to experience measurable cognitive changes in preclinical Alzheimer's disease trials. Casey Vanderlip, an MD/PhD student at the University of California, Irvine, presented findings indicating that these assessments can capture subtle differences in cognitive function alongside biological markers. The study utilized data from two large preclinical Alzheimer's disease trials, AHEAD and A4, which collected digital cognitive assessments and amyloid and tau PET imaging. The research found that while attention and psychomotor speed were largely unaffected across disease stages in this highly selective population, memory appeared particularly sensitive to underlying disease progression. Individuals with medial temporal tau showed intermediate cognitive differences, and those with neocortical tau exhibited the clearest deficits.

Banner Alzheimer's Institute Celebrates 20 Years of Pioneering Research and Patient Care

Banner Alzheimer's Institute Celebrates 20 Years of Pioneering Research and Patient Care

Banner Alzheimer's Institute is celebrating its 20th anniversary, marking two decades of significant contributions to Alzheimer's research, prevention, treatment, and care. Established in 2006, the institute has grown from its Phoenix origins into an internationally recognized leader in neurological conditions, including Alzheimer's and Parkinson's disease. Its mission focuses on ending Alzheimer's, establishing new standards of care, and fostering biomedical collaboration. The institute has played a crucial role in advancing therapies approved by the U.S. Food and Drug Administration for Alzheimer's and related dementias. Key achievements include pioneering prevention trials, developing groundbreaking biomarker blood tests for early detection, and implementing scalable programs to return Alzheimer's risk results directly to patients. Banner Health, a nonprofit health system, emphasizes making cutting-edge science accessible to everyday people, including underserved populations, through community programs ...

USC and Indiana University Collaborate on Alzheimer's Disease Research and Clinical Trials

USC and Indiana University Collaborate on Alzheimer's Disease Research and Clinical Trials

The University of Southern California (USC) and Indiana University (IU) are engaged in extensive collaborative research focused on Alzheimer's disease and other dementia-related conditions. USC's Keck School of Medicine Professor of Neurology Paul Aisen, who also directs the USC Epstein Family Alzheimer's Therapeutic Research Institute, is working with multiple IU School of Medicine colleagues on various projects. These include the Alzheimer's Plasma Extension Study, which tracks Alzheimer's-related blood biomarkers and cognitive function, and the Alzheimer's Clinical Trials Consortium, a network designed to foster innovation in disease research. Additionally, collaborations extend to the Alzheimer's Tau Platform clinical trial, evaluating new treatments to reduce protein buildup in the brain, and the Longitudinal Follow-up of Clinical Trial Participants for Brain Donation. USC Professor of Clinical Neurology Michael S. Rafii has also partnered with IU researchers on a clinical trial to prevent Alzheimer's...

UT San Antonio Hosts International Conferences Advancing Dementia and Stroke Research

UT San Antonio Hosts International Conferences Advancing Dementia and Stroke Research

The University of Texas at San Antonio (UT San Antonio) recently hosted two international brain health conferences from October 5-10, bringing together researchers from around the world. These conferences focused on the biological processes underlying Alzheimer’s disease, related dementias, and stroke. The events aimed to strengthen collaborations among scientists to translate scientific discoveries into improved diagnosis, treatment, and prevention strategies. Nearly 100 speakers, including almost 30 researchers from UT San Antonio, participated, underscoring the university's significant role in advancing research into brain aging and neurological diseases. The meetings highlighted the opportunities and challenges in brain health research, emphasizing the need for continued efforts to turn scientific findings into better patient care.

UVA Health Research Identifies Gene's Role in Alzheimer's Disease Progression

UVA Health Research Identifies Gene's Role in Alzheimer's Disease Progression

New research from UVA Health suggests that a specific gene, CASS4, plays a crucial role in the development of Alzheimer's disease. Researchers, led by John Lukens, Ph.D., investigated the CASS4 gene after it was identified as an Alzheimer's risk factor in multiple studies. Their findings indicate that CASS4 helps direct microglia, which are brain-cleaning immune cells. When the gene's function is disrupted, microglia become less effective at responding to harmful amyloid-beta plaques forming in the brain. This impairment prevents microglia from adequately containing and compacting these toxins, leading to faster growth and more aggressive spread of the plaques. The study, published in the Journal of Experimental Medicine, highlights that defective CASS4 activity may serve as an early-onset biomarker for Alzheimer's and suggests that therapeutic strategies aimed at boosting its function could offer a new treatment approach. The research involved lab mice, where impaired CASS4 led to amyloid-beta buildup, ha...

Early-Onset Alzheimer's Patients Exhibit Faster Tau Buildup, More Aggressive Progression

Early-Onset Alzheimer's Patients Exhibit Faster Tau Buildup, More Aggressive Progression

A recent study has revealed that individuals diagnosed with early-onset Alzheimer's disease, before the age of 65, experience a significantly faster accumulation and wider spread of tau protein tangles in their brains compared to those with late-onset Alzheimer's. Tau is a natural protein that, when misbehaving, forms damaging tangles and clumps inside brain cells, a key marker of Alzheimer's. The study, published in Science Translational Medicine and supported by the National Institute on Aging, found that tau builds up at more than twice the rate in younger patients. This rapid buildup explains why early-onset patients often face a quicker decline in function and may present with unusual, non-memory-related symptoms initially, such as difficulties with reading, judging distances, or executive functions, unlike the memory-dominant symptoms typical of late-onset cases.

University of Virginia Study Identifies CASS4 Gene as Potential Target for Slowing Alzheimer's Progression

University of Virginia Study Identifies CASS4 Gene as Potential Target for Slowing Alzheimer's Progression

A recent study conducted by the University of Virginia's Harrison Family Translational Research Center in Alzheimer's and Neurodegenerative Diseases has identified the CASS4 gene as a potential new target for slowing the progression of Alzheimer's disease. The research, primarily conducted in mice, found that CASS4 plays a crucial role in enabling microglia, the brain's immune cells, to effectively contain and compact neurotoxic amyloid-beta aggregates. When the CASS4 gene was disrupted in mice, microglia became less efficient, leading to a more aggressive spread of amyloid plaques, neuronal damage, and cognitive decline. John Lukens, the director of the center, stated that while CASS4 was previously known as an Alzheimer's risk gene, its specific function in brain health was not well understood until this study. The findings suggest that therapies designed to boost CASS4 activity in microglia could offer a novel strategy to limit Alzheimer's progression.